SAN CARLOS, Calif., May 13, 2021 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, today reported financial results for the first quarter of 2021 and filed its quarterly report on Form 10-Q for the three months ended March […]
Financial
Liquidia Reports First Quarter 2021 Financial Results and Provides Corporate Update
– Doubled the market opportunity for Treprostinil Injection by adding subcutaneous delivery – Resubmitted New Drug Application for LIQ861 (treprostinil) Inhalation Powder – Improved financial position with private placement and access to new credit facility – Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C., May […]
Acutus Medical Reports First Quarter 2021 Financial Results
CARLSBAD, Calif., May 12, 2021 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the first quarter of 2021. Recent Highlights: Reported revenue of $3.6 million in the […]
ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update
Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 WESTMINSTER, Colo., May 11, 2021 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today […]
scPharmaceuticals Inc. Reports First Quarter 2021 Financial Results and Provides Business Update
FREEDOM clinical study on track for topline results in Q3 2021 Ended Q1 with cash, cash equivalents, restricted cash and investments of $96.5 million BURLINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to […]
InspireMD Announces Appointment of Katie Arnold to Board of Directors
TEL AVIV, Israel, May 12, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced it has appointed seasoned marketing executive Kathryn (Katie) Arnold to its Board of Directors. […]
Caladrius Biosciences Receives $1.4 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program
BASKING RIDGE, N.J., May 12, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that it has received $1.4 million in non-dilutive funding as an approved participant of the […]
InspireMD Announces First Quarter 2021 Financial Results
Company Completes Up-List to Nasdaq Capital Market, with Trading Becoming Effective May 21, 2021 Management to host investor conference call today, May 11, 2021, at 8:30am ET TEL AVIV, Israel, May 11, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for […]
UltraSight Raises $13 million to Bring AI Guidance for Cardiac Ultrasound to Patient Point of Care
Digital Health company transforming ultrasound industry TEL AVIV, Israel, May 11, 2021 /PRNewswire/ — UltraSight (formerly OnSight Medical), a Digital Health pioneer for cardiac imaging and beyond, announced today that it has closed a $13 million Series B funding round. The investment will be used to advance U.S. clinical programs for its real time, AI guidance […]
CytoSorbents Awarded $1.5 Million Sequential Phase II SBIR Contract to Advance the Treatment of Severe Hyperkalemia in Traumatic Injury
MONMOUTH JUNCTION, N.J., May 11, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® and other blood purification technologies to treat deadly conditions in critically-ill and cardiac surgery patients around the world, announced the U.S Army Medical Research and Development Command has awarded CytoSorbents a Defense Health Agency (DHA) Sequential Phase […]
Recent
Microbot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic System
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke
Popular
- No commented posts yet